Drug Profile
Research programme: therapeutic antiviral vaccines - Abivax/CIGB
Alternative Names: ABX-318; anti-HPV vaccine - Abivax/CIGBLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator BC Cancer Agency; Wittycell
- Developer Abivax; Cuban Center for Genetic Engineering and Biotechnology; Wittycell
- Class Papillomavirus vaccines
- Mechanism of Action Immunostimulants; Natural killer cell receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cervical cancer; Cervical dysplasia; Human papillomavirus infections
Most Recent Events
- 28 Mar 2023 Discontinued - Preclinical for Cervical cancer (Prevention) in France (unspecified route) (Abivax Pipeline, March 2023)
- 28 Mar 2023 Discontinued - Preclinical for Cervical dysplasia in France (unspecified route) (Abivax Pipeline, March 2023)
- 28 Mar 2023 Discontinued - Preclinical for Human papillomavirus infections in France (unspecified route)(Abivax Pipeline, March 2023)